These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: B-Cell suppression in adult mice injected with anti-delta followed by anti-mu mAb.
    Author: Chentoufi AA, Nizet Y, Havaux X, Nisol F, Bazin H, Latinne D.
    Journal: Cell Immunol; 2000 Oct 10; 205(1):40-51. PubMed ID: 11078606.
    Abstract:
    Cross-linking of surface IgM or IgD B-cell receptors (BCR) with appropriate anti-Ig antibodies induces IgM(high) or IgD(high) B-cell depletion, respectively. The aim of this paper is to analyze how injections of anti-delta followed by anti-mu monoclonal antibodies (mAb) can deplete and suppress B cells and then induce T-independent type 2 antigen tolerance in adult mice even after treatment is stopped. The experimental protocol consisted of three daily injections of anti-delta mAb followed by repeated injections of anti-mu mAb. It shows that a sequential injection of anti-delta and anti-mu mAb induces B-cell depletion and T-independent type 2 response downregulation. Morever, the T-dependent response is maintained, except for the IgG3 isotype. After clearance of the anti-delta mAb from the circulation, B cells reappear as an IgD(+) IgM(-) B-cell population in the bone marrow (BM) and spleen. The origin of IgD(+) IgM(-) cells was studied in scid mouse transfer models. We show that IgD(+) IgM(-) B cells are not mature cells reexpressing sIgD but BM-derived cells that require a T-cell presence to be developed. The lack of sIgM expression by posttranscriptional regulation and the need of T-cell help for escaping anti-mu negative selection suggest strongly that this population had properties similar to those of anergized B cells. These results support the potential use of sequential injections of anti-delta and anti-mu in the prevention of xenograft rejection.
    [Abstract] [Full Text] [Related] [New Search]